A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

NCT03220347 | Terminated Phase 1 FDA Drug

• 3 other identifiers: CC-90010-ST-001U1111-1194-85702015-004371-79
• Study Type: interventional
• Target: 139
• Locations: 4 countries
• Sites: 11

Brief Summary

Study CC-90010-ST-001 is an open-label, Phase 1a, dose escalation and expansion, First-in-human (FIH) clinical study of CC-90010 in subjects with advanced or unresectable solid tumors and relapsed and/or refractory advanced Non-Hodgkin's lymphoma (NHL). The dose escalation part (Part A) of the study will explore escalating oral doses of CC-90010 to estimate the maximum tolerated dose (MTD) of CC-90010. The expansion part (Part B) will further evaluate the safety and efficacy of CC-90010 administered at or below the MTD in the following cohorts: Cohort 1: relapsed and/or refractory DLBCL approximately 20-25 evaluable subjects at 45 mg CC-90010 4-days-on/24-days-off in each 28-day cycle Cohort 2: advanced BCC -enrollment stopped due to recruitment challenges Cohort 3: relapsed and/or refractory DLBCL -approximately 15 evaluable subjects at 30mg CC-90010 3-dayson/11-days-offin each 28-day cycle. The enrollment of subjects with R/R DLBCL in Cohort 1 and Cohort 3 was closed due to Company's strategic decision and not due to any safety concern or lack of preliminary antitumor efficacy. The food effect assessment (Part C, Spain only) will evaluate the impact of food on CC-90010 when administered at the RP2D of 45 mg 4-days-on/24-days-off (180 mg per 28-day cycle), by comparison of the PK parameters following fasted and fed (high-fat, high-calorie meal) conditions.

Conditions

Lymphoma, Non-Hodgkin; Neoplasms

Keywords

Non-Hodgkin's Lymphomas; Safety; Efficacy; CC-90010; Solid Tumors; Relapsed/Refractory

Outcome Measures

Primary Outcomes (3)

• Adverse Events (AEs)

  Number of participants with adverse events

  Up to 7 years

• Dose Limiting Toxicities (DLTs)

  A DLT is defined as any of the toxicities described in the protocol occurring within the DLT assessment unless the event can clearly be determined to be unrelated to CC-90010

  Up to 7 years

• Maximum tolerated dose (MTD)

  The MTD is the highest dose that causes DLTs in not more than 33% of the subjects treated with CC-90010 in the first cycle with at least 6 evaluable subjects treated at this dose.

  Up to 7 years

Secondary Outcomes (15)

• Clinical benefit rate (CBR)

  Up to 7 years

• Objective response rate (ORR)

  Up to 7 years

• Duration of Response Rate

  Up to 7 years

• Duration of stable disease

  Up to 7 years

• Progression-free survival (PFS)

  Up to 7 years

Study Arms (1)

CC-90010 in patients with solid tumors and NHL

EXPERIMENTAL

Subjects will be administered orally once daily for 3 consecutive days followed by 4 consecutive days off drug every week (3/7-days schedule) in each 28 day cycle in Part A. Alternative dosing schedules (eg, 2-days-on/5-days- off each week, 3-days-on/4-days-off every other week, 4-days on/24 days off) may be evaluated one dosing schedule at a time or ≥ 2 dosing schedules given in parallel, based on the review of available safety, PK, pharmacodynamic (PD), and efficacy data.

Drug: CC-90010

Interventions

CC-90010 DRUG

CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

CC-90010 in patients with solid tumors and NHL

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age = or \> 18 years.
• For subjects enrolling in food-effect assessment (Part C) only: a. Subject must agree and be willing to consume a standard high-fat, high-calorie meal. b. Subject must be willing to refrain from caffeine or xanthene-containing products (coffee, tea, cola, chocolate, etc.) for 48 hours prior to dosing on Cycle 1 Day 4 and Cycle 2 Day 4 and up to 24 hours post dose.
• Subjects with histological or cytological confirmation of either:
• In Part A, advanced or unresectable solid tumors or advanced relapsed and/or refractory Non-Hodgkin lymphoma (ie, Diffuse large B-cell lymphoma and Follicular lymphoma or Marginal zone lymphoma) including those who have progressed on (or not been able to tolerate due to medical comorbidities or unacceptable toxicity) standard anticancer therapy or for whom no other approved conventional therapy exists.
• In Part B dose expansion, - Cohorts 1 and 3: relapsed and/or refractory DLBCL following at least 2 prior lines of therapy (e.g. have failed at least one line of standard therapy and have received at least one prior line of salvage therapy) OR have failed at least one prior line of standard therapy and are not eligible for autologous stem cell transplant (ASCT) or have declined ASCT; transformed lymphoma following chemotherapy for lower grade lymphoma and at least two standard treatment regimen for DLBCL.
• Subjects with two or more lines of systemic therapy must have been treated with and have lack of response after chimeric antigen receptor (CAR) T-cell therapy, if such therapy is available, OR be ineligible for CAR T-cell therapy at the time of enrollment, OR subject declined CAR T-cell therapy.
• \- Cohort 2: advanced basal cell carcinoma including those who have progressed on (or not been able to tolerate due to medicalcomorbidities or unacceptable toxicity) standard anticancer therapy or for whom no other approved conventional therapy exists.
• In Part C, advanced or unresectable solid tumors including those who have progressed on (or not been able to tolerate due to medical comorbidities or unacceptable toxicity) standard anticancer therapy or for whom no other approved conventional therapy exist
• At least one site of measurable disease for subjects with solid tumors; bi-dimensionally measurable disease on cross sectional imaging with at least one lesion \>1.5 cm for subjects with NHL. For subjects with rare malignancies evaluable disease can be considered.
• Tumor biopsies whenever safe and feasible will be collected in Part A, except for subjects with GBM. Subject consents to mandatory tumor biopsies (Screening and on treatment) in Part B. In exceptional circumstances an exemption waiver may be granted by the Sponsor for this criterion
• ECOG PS of 0 to 1.
• Females of childbearing potential (FCBP)1 must:
• Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner), one of which must be barrier, from signing the ICD, throughout the study (including dose interruptions), and for up to 6 months and 16 days following the last dose of CC-90010; and
• Avoid conceiving for 6 months and 16 days after the last dose of CC-0010.
• Agree to not donate oocytes while receiving CC-90010 and for 6 months and 16 days after the last dose of CC-90010.

You may not qualify if:

• Subject has received anti-cancer therapy (either approved or investigational) within \<or= 4 weeks or 5 half-lives, whichever is shorter prior to starting CC-90010.
• Subject has received prior CAR T-cell therapy or other T-cell targeting treatment (approved or investigational) ≤ 4 weeks prior to starting CC-90010.
• Toxicities resulting from prior systemic cancer therapies must have resolved. to ≤ NCI CTCAE Grade 1 prior to starting CC-90010 treatment
• Subject has received autologous hematologic stem cell transplant (HSCT) \<or= 3 months prior to starting CC-90010 treatment. Subjects with allogeneic HSCT will not be allowed on this protocol.
• Major surgery \<or= 4 weeks or minor surgery \<or= 2 weeks prior to starting CC-90010 or subjects who have not recovered from surgery.
• Completed radiation treatment \< 4 weeks prior to starting CC-90010.
• Symptomatic, untreated, or unstable central nervous system (CNS) metastases.
• Known symptomatic acute or chronic pancreatitis.
• Impaired cardiac function or clinically significant cardiac diseases.
• Pregnant or nursing females.
• \. History of concurrent second cancers requiring active, ongoing systemic treatment.
• \. History of clinically significant cognitive disorder(s) or active cognitive disorder(s).
• \. Evidence of history of bleeding diathesis. 14. Subjects with known prior episodes of non-arteritic anterior ischemic optic neuropathy (NAION) should be excluded from the study. CC-90010 should be used with caution in subjects with retinitis pigmentosa 15. Any significant medical condition that would prevent the subject from participating (or compromise compliance) in the study or would place the subject at unacceptable risk if he/she were to participate in the study.
• \. Patients with poor bone marrow reserve as assessed by the Investigator such as in the following conditions:
• Having received extensive bone radiotherapy

Sponsors & Collaborators

• Celgene: lead

Study Sites (11)

Local Institution - 102

Bordeaux, 33076, France

Location

Local Institution - 100

Villejuif, 94805, France

Location

Local Institution - 303

Meldola, 47014, Italy

Location

Local Institution - 301

Napoli, Campania, 80131, Italy

Location

Local Institution - 302

Rozzano (MI), 20089, Italy

Location

Local Institution - 400

Kashiwa-shi, Chiba, 2778577, Japan

Location

Local Institution - 402

Koto-ku, Tokyo, 1358550, Japan

Location

Local Institution - 401

Chikusa-ku, 464-8681, Japan

Location

Local Institution - 200

Barcelona, 08035, Spain

Location

Local Institution - 201

Madrid, 28040, Spain

Location

Local Institution - 202

Madrid, 28041, Spain

Location

Related Links

• BMS Clinical Trial Information
• BMS Clinical Trial Patient Recruiting

MeSH Terms

Conditions

Lymphoma, Non-Hodgkin; Neoplasms; Recurrence

Condition Hierarchy (Ancestors)

Lymphoma; Neoplasms by Histologic Type; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Bristol-Myers Squibb

  Bristol-Myers Squibb

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 14, 2017
• First Posted: July 18, 2017
• Study Start: July 24, 2017
• Primary Completion: September 6, 2024
• Study Completion: September 6, 2024
• Last Updated: October 8, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

FR (2); JP (3); IT (3); ES (3)